The Dynamics of Human Atrial Fibrillation
Recruiting · NCT05366361 · Observational (researchers observe without assigning treatment) · Lead sponsor: Stanford University
View the official record on ClinicalTrials.gov →What this trial is about
Atrial fibrillation (AF) is an enormous public health problem in the United States, affecting 2-5 million Americans and causing rapid heart beats, stroke, heart failure or death. In this project, the applicant will develop a novel framework to better understand human AF that builds on agreement between several concepts for the disease. The applicant will develop strategies to identify AF patients who will best respond to each of several therapies, to guide personalized therapy.
Who can take part
Age range
22 Years to 80 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- referred for ablation or Maze surgery at Stanford Medicine for persistent AF (i.e. which requires cardioversion to terminate and/or lasts \>7 days)
- Per our clinical practice and guidelines (Calkins et al., Heart Rhythm 2018), patients will have failed or be intolerant of \>or= 1 anti-arrhythmic drug. Patients after Maze surgery typically have failed prior endocardial ablation.
Exclusion criteria
- active coronary ischemia or decompensated heart failure
- atrial or ventricular clot on trans-esophageal echocardiography
- pregnancy (to minimize fluoroscopic exposure)
- inability or unwillingness to provide informed consent
- rheumatic valve disease (results in a unique AF phenotype)
- thrombotic disease or venous filters
- prior chest surgery is a relative contraindication for Maze surgery
Where it is running
1 location listed across 1 US state.
- Stanford University - Stanford, California, United States